Search Result
Results for "
Peptide R
" in MedChemExpress (MCE) Product Catalog:
21
Biochemical Assay Reagents
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P4111
-
|
|
CXCR
|
Cancer
|
|
Peptide R, a cyclic peptide, is a specific CXCR4 antagonist. Peptide R shows outstanding capacities to profoundly remodel the tumor stroma. Peptide R has the potential for tumor research .
|
-
-
- HY-P4111A
-
|
|
CXCR
|
Cancer
|
|
Peptide R (TFA) is a synthetic and specific CXCR4 antagonist. Peptide R (TFA) shows outstanding capacities to remodel the tumor stroma. Peptide R (TFA) can be used for solid tumor (glioblastoma, etc.) research .
|
-
-
- HY-P0133B
-
|
Nona-L-arginine acetate; Peptide R9 acetate
|
Ser/Thr Protease
|
Neurological Disease
|
|
(Arg)9 (Nona-L-arginine) acetate is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 acetate has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model .
|
-
-
- HY-P0133A
-
|
Nona-L-arginine TFA; Peptide R9 TFA
|
Ser/Thr Protease
|
Neurological Disease
|
|
(Arg)9 (Nona-L-arginine) TFA is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 TFA has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model .
|
-
-
- HY-P10510A
-
-
-
- HY-P10723
-
-
-
- HY-P11011
-
|
Pep R54; CXCR4 antagonist Peptide 19
|
CXCR
|
Cancer
|
|
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC50=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .
|
-
-
- HY-P10973
-
|
|
CXCR
ERK
|
Cancer
|
|
Peptide R analogue 10 (compound 10) is an analog of the CXCR4 antagonist peptide Peptide R (HY-P4111) with stronger antagonistic potency, specificity and plasma stability. Peptide R analogue 10 can inhibit CXCL12-mediated cell migration, ERK phosphorylation and CXCR4 internalization. Peptide R analogue 10 can be used in the study of CXCR4 overexpressing leukemia and colon cancer .
|
-
-
- HY-P0133
-
|
Nona-L-arginine; Peptide R9
|
Ser/Thr Protease
|
Neurological Disease
|
|
(Arg)9 (Nona-L-arginine) is a cell-penetrating peptide (CPP) made up of 9 arginine residues, which is an inhibitor of serine endoprotease Furin. (Arg)9 has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model .
|
-
-
- HY-P10510
-
-
-
- HY-P3918
-
|
|
p38 MAPK
|
Others
|
|
EGF-R (661-681) T669 Peptide is a MAPK substrate that can used to measure MAPK catalytic activity .
|
-
-
- HY-172673
-
|
|
GCGR
|
Metabolic Disease
|
|
GLP-1R agonist 31 (Compound 1) is an amorphous glucagon-like peptide-1 receptor (GLP-1R) agonist .
|
-
-
- HY-168585
-
-
-
- HY-147625
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
GLP-1R agonist 12 (Compound 123) is an agonist of glucagon-like peptide-1 receptors (GLP-1R). GLP-1R agonist 12 can be used for diabetes research .
|
-
-
- HY-P3291
-
|
ZP7570
|
GCGR
|
Metabolic Disease
|
|
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .
|
-
-
- HY-116819A
-
|
|
GCGR
|
Metabolic Disease
|
|
VU0453379 hydrochloride is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of glucagon-like peptide-1R (GLP-1R) with an EC50 of 1.3 μM .
|
-
-
- HY-116819
-
|
|
GCGR
|
Metabolic Disease
|
|
VU0453379 is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of glucagon-like peptide-1R (GLP-1R) with an EC50 of 1.3 μM .
|
-
-
- HY-112679
-
|
|
GCGR
|
Others
|
|
GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.
|
-
-
- HY-P11453
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
R9H6 is a peptide containing nine arginine peptides and six histidine peptides. The LP(R9H6)m nanocomplex containing R9H6 exhibits high efficiency in mRNA delivery. R9H6 can be used in the research of anaplastic thyroid cancer .
|
-
-
- HY-P3506
-
|
LY3437943
|
GCGR
GLP Receptor
|
Metabolic Disease
|
|
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .
|
-
-
- HY-P3506B
-
|
LY3437943 acetate
|
GCGR
GLP Receptor
|
Metabolic Disease
|
|
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .
|
-
-
- HY-P3506A
-
|
LY3437943 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .
|
-
-
- HY-144035
-
|
|
GCGR
|
Cancer
|
|
GLP-1R agonist 4 is a potent agonist of GLP-1R. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 has the potential for the research of diabetes (extracted from patent WO2019239319A1, compound 96) .
|
-
-
- HY-162436
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
GLP-1R agonist 21 (Compound I-134) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0104 nM .
|
-
-
- HY-162435
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
GLP-1R agonist 20 (Compound I-132) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0162 nM .
|
-
-
- HY-162437
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
GLP-1R agonist 22 (Compound I-135) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0165 nM .
|
-
-
- HY-144034
-
|
|
GCGR
|
Metabolic Disease
|
|
GLP-1R agonist 3 is a potent agonist of GLP-1R. GLP-1R agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1) .
|
-
-
- HY-144033
-
|
|
GCGR
|
Metabolic Disease
|
|
GLP-1R agonist 1 is a potent agonist of GLP-1R. GLP-1R agonist 1 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 1 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 4) .
|
-
-
- HY-112185
-
|
LY3502970; GLP-1 receptor agonist 1
|
GCGR
|
Metabolic Disease
|
|
Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete .
|
-
-
- HY-125824
-
|
PF-06882961
|
GCGR
|
Metabolic Disease
|
|
Danuglipron (PF-06882961) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron has the potential for type 2 diabetes research .
|
-
-
- HY-P10116
-
|
APTscr-9R
|
STAT
|
Others
|
|
APTSTAT3-9R, scrambled (APTscr-9R) is a control peptide that forms a structure similar to that of APTSTAT3-9R but possesses a scrambled sequence in the target-binding region .
|
-
-
- HY-P5329
-
|
|
NADPH Oxidase
|
Others
|
|
r8-Gly-Noxa A BH3 is a biological active peptide. (This cell permeable peptide is derived from the BH3 domain (a death domain) of Noxa A, amino acid residues 17 to 36. Eight D-Arginine residues and a Glycine linker residue are added to the amino terminal of the peptide.)
|
-
-
- HY-142162
-
|
|
GCGR
|
Metabolic Disease
|
|
LSN3318839 is an orally active positive modulator of the glucagon-like peptide-1 receptor (GLP-1R). LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar .
|
-
-
- HY-125824A
-
|
PF-06882961 tromethamine
|
GCGR
|
Metabolic Disease
|
|
Danuglipron (PF-06882961) tromethamine is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron tromethamine has the potential for type 2 diabetes research .
|
-
-
- HY-176770
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
GLP-1R agonist 34 (Compound 1) is an orally active small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R agonist 34 promotes insulin secretion, inhibits glucagon release, and delays gastric emptying, thereby effectively lowering blood glucose levels. GLP-1R agonist 34 is promising for research of metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
-
- HY-171850
-
|
|
GLP Receptor
|
Metabolic Disease
Inflammation/Immunology
|
|
GLP-1R modulator-1 (Compound 384) is an orally active, potent selective glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R modulator-1 activates G-protein coupled signaling, elevates intracellular cAMP levels, promotes insulin secretion, delays gastric emptying and suppresses appetite. GLP-1R modulator-1 is promising for research of type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
-
- HY-142162A
-
|
|
GCGR
|
Metabolic Disease
|
|
(S,R)-LSN3318839 is the stereoisomer of LSN3318839 (HY-142162). LSN3318839 is an orally active positive modulator of the glucagon-like peptide-1 receptor (GLP-1R). LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar .
|
-
-
- HY-172276A
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG2000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG2000-R8 can be used for drug delivery .
|
-
-
- HY-172276
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG1000-R8 can be used for drug delivery .
|
-
-
- HY-172276C
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG3400-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG3400-R8 can be used for drug delivery .
|
-
-
- HY-172276B
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG5000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG5000-R8 can be used for drug delivery .
|
-
-
- HY-P5438
-
|
|
Btk
c-Kit
FAK
FLT3
Insulin Receptor
|
Others
|
|
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)
|
-
-
- HY-143312
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
V-0219 (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). V-0219 can be used for obesity-associated diabetes research .
|
-
-
- HY-143312A
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
V-0219 hydrochloride (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). V-0219 hydrochloride can be used for obesity-associated diabetes research .
|
-
-
- HY-172277B
-
|
|
Liposome
|
Neurological Disease
|
|
DSPE-PEG5000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG5000-R9 can be used for drug delivery .
|
-
-
- HY-172277A
-
|
|
Liposome
|
Neurological Disease
|
|
DSPE-PEG2000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG2000-R9 can be used for drug delivery .
|
-
-
- HY-172277C
-
|
|
Liposome
|
Neurological Disease
|
|
DSPE-PEG3400-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG3400-R9 can be used for drug delivery .
|
-
-
- HY-172277
-
|
|
Liposome
|
Neurological Disease
|
|
DSPE-PEG1000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG1000-R9 can be used for drug delivery .
|
-
-
- HY-109022A
-
|
(3R,5R,6S)-MK-8031; (3R,5R,6S)-AGN-241689
|
CGRP Receptor
|
Neurological Disease
|
|
(3R,5R,6S)-Atogepant ((3R,5R,6S)-MK-8031) is the enantiomer of Atogepant (HY-109022). Atogepant is a calcitonin gene-related peptide receptor (CGRP) antagonist. Atogepant can be used for researching migraine.
|
-
-
- HY-P11031
-
|
|
Fungal
|
Infection
|
|
CotH3 peptide is a functional peptide unique to Mucorales that binds to the host GRP78 receptor and allows them to invade endothelial cells. CotH3 peptide–targeted monoclonal antibodies protect immunosuppressed mice from mucormycosis caused by R. delemar and other Mucorales. CotH3 peptide also synergizes with antifungal drugs to protect mice with diabetic ketoacidosis (DKA) from R. delemar infection .
|
-
- HY-W591317
-
|
(R)-NODAG
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
(R)-NODAGA-tris(t-Bu ester) ((R)-NODAG) is a NODAGA derivative. (R)-NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .
|
-
- HY-P991511
-
|
|
PACAP Receptor
|
Neurological Disease
|
|
ALD1910 is a humanized monoclonal antibody against PACAP38 and PACAP27. ALD1910 blocks PACAP signaling through the pituitary adenylate cyclase-activating peptide type I receptor (PAC1-R), vasoactive intestinal peptide receptor 1 (VPAC1-R), and VPAC2-R. ALD1910 recognizes a nonlinear epitope within PACAP and blocks its binding to the cell surface. ALD1910 can be used for the study of PACAP-mediated migraine .
|
-
- HY-101116
-
|
|
GCGR
|
Metabolic Disease
|
|
GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM .
|
-
- HY-P10392AF
-
|
|
Wnt
β-catenin
|
Cancer
|
|
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
|
-
- HY-P1285
-
|
Con-R
|
iGluR
|
Neurological Disease
|
|
Conantokin R (Con-R) is an NMDA receptor peptide antagonist with an IC50 of 93 nM. Conantokin R binds Zn 2+ and Mg 2+ with Kds of 0.15 μM and 6.5 μM, respectively. Conantokin R shows anticonvulsant activity .
|
-
- HY-P11043
-
|
|
GLP Receptor
Neuropeptide Y Receptor
Arrestin
|
Metabolic Disease
|
|
GEP44 is a peptide biased triple agonist targeting Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R). GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .
|
-
- HY-P10392
-
|
|
β-catenin
Wnt
|
Cancer
|
|
aStAx-35R, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells .
|
-
- HY-P10168
-
|
|
Phosphatase
|
Others
|
|
11R-CaN-CON is a control inactive peptide and can be used as a negative control for 11R-CaN-AID (HY-P10167) .
|
-
- HY-P0242
-
-
- HY-P10302A
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC50 is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC50 is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
- HY-172272B
-
|
|
Liposome
VEGFR
|
Cancer
|
|
DSPE-PEG5000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-172272A
-
|
|
Liposome
VEGFR
|
Cancer
|
|
DSPE-PEG2000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-P2282
-
|
|
STAT
|
Cancer
|
|
APTSTAT3-9R, a specific STAT3-binding peptide, inhibits STAT3 activation and downstream signaling by specifically blocking STAT3 phosphorylation. APTSTAT3-9R exerts antiproliferative effects and antitumor activity .
|
-
- HY-172272
-
|
|
Liposome
VEGFR
|
Cancer
|
|
DSPE-PEG1000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-172272C
-
|
|
Liposome
VEGFR
|
Cancer
|
|
DSPE-PEG3400-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-158077
-
|
(R)-tetraMe-DOTA
|
Biochemical Assay Reagents
|
Others
|
|
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.
|
-
- HY-108501
-
|
|
Somatostatin Receptor
|
Neurological Disease
|
|
(1R,1'S,3'R/1R,1'R,3'S)-L-054,264 is a selective non-peptide human somatostatin receptor subtype 2 (sst2) agonist. (1R,1'S,3'R/1R,1'R,3'S)-L-054,264 can be used in the study of retinal neuromodulation .
|
-
- HY-P0242A
-
-
- HY-P10392B
-
|
|
β-catenin
Wnt
|
Cancer
|
|
aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells .
|
-
- HY-112185A
-
|
LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate
|
GCGR
|
Metabolic Disease
|
|
Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete .
|
-
- HY-P1504
-
-
- HY-18678A
-
|
PT-141 Acetate
|
Melanocortin Receptor
|
Endocrinology
|
|
Bremelanotide Acetate (PT-141 Acetate), a synthetic peptide analogue of α-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R for the treatment of sexual dysfunction .
|
-
- HY-45894
-
|
Semaglutide side chain
|
GLP Receptor
|
Metabolic Disease
|
|
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is an intermediate in the synthesis of the glucagon-like peptide 1 receptor (GLP-1R) agonist Semaglutide (HY-114118).
|
-
- HY-P11044
-
|
|
GCGR
Neuropeptide Y Receptor
|
Metabolic Disease
|
|
GEP12 is a GLP-1R/Y1-R/Y2-R tri-receptor agonist peptide with an EC50 of 17.3 nM and an IC50 of 19.2 nM for receptor binding. GEP12 may promote glycemic control and weight loss .
|
-
- HY-P1504A
-
-
- HY-P10830
-
-
- HY-P11285
-
|
Long acting GIPRA-1
|
Insulin Receptor
|
Metabolic Disease
|
|
LAGIPRA peptide is a long-acting GIP1R agonist. LAGIPRA peptide enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide has the potential for the research of type 2 diabetes .
|
-
- HY-P11245
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
NN1213 (Peptide 21), a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with an EC50 of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 significantly reduces appetite in rat and dog models. NN1213 can be used for antiobesity research .
|
-
- HY-129657
-
|
|
GCGR
|
Metabolic Disease
|
|
GLP-1 receptor agonist 4 is a glucagon-like peptide-1 receptor (GLP-1R) agonist extracted from patent WO2009111700A2, compound 87, has an EC50 of 64.5 nM. GLP-1 receptor agonist 4 can be used in the research for treatment of diabetes .
|
-
- HY-P11245A
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
NN1213 acetate (Peptide 21), a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with an EC50 of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 acetate significantly reduces appetite in rat and dog models. NN1213 acetate can be used for antiobesity research .
|
-
- HY-P10302
-
|
|
GLP Receptor
Insulin Receptor
|
Metabolic Disease
|
|
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
- HY-P3539
-
|
|
GCGR
|
Neurological Disease
Endocrinology
|
|
Exendin-4 (3-39) is a peptide. Exendin-4 (3-39) is a truncated form of Exendin-4 (HY-13443) that lacks the first two amino acids. Exendin-4 is a potent Glucagon-like peptide-1 receptor (GLP-1r) agonist. Exendin-4 (3-39) and Exendin-4 can be used for the research of diabetic and hypothalamic-pituitary-adrenal (HPA) axis .
|
-
- HY-P0264A
-
|
Avexitide acetate
|
GLP Receptor
|
Metabolic Disease
|
|
Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research .
|
-
- HY-P3226
-
|
|
IGF-1R
|
Metabolic Disease
|
|
JB-1, an IGF-1 peptide analog, is a selective and potent IGF-1R antagonist. JB-1 competes with IGF-1 by binding the IGF-1 receptor. JB-1 prevents the autophosphorylation of IGF-1R, and has no activity in IGF-II .
|
-
- HY-15016
-
|
|
Oxytocin Receptor
|
Endocrinology
|
|
(E/Z)-OT-R antagonist 1 is a mixture of E/Z forms of OT-R antagonist 1 (HY-15015). OT-R antagonist 1 is a novel, potent, selective non-peptide OT-R antagonist that inhibits oxytocin-induced intracellular Ca 2+ activation (IC50 = 8 nM) .
|
-
- HY-P1205
-
|
Melanin-concentrating hormone(human, mouse, rat)
|
MCHR1 (GPR24)
|
Neurological Disease
|
|
MCH (human, mouse, rat) is a potent peptide agonist of MCH-R and exhibits binding IC50 values of 0.3nM and 1.5 nM for MCH1R and MCH2R, respectively. MCH (human, mouse, rat) is a highly sensitive to MCH-2R in a CHO cell line and monitoring mobilization of intracellular calcium with FLIPR, exhibits functional activation EC50 values of 3.9 nM and 0.1nM for human MCH-1R and MCH-2R, respectively .
|
-
- HY-P11285A
-
|
Long acting GIPRA-1 TFA
|
Insulin Receptor
|
Metabolic Disease
|
|
LAGIPRA peptide TFA is a long-acting GIP1R agonist. LAGIPRA peptide TFA enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide TFA has the potential for the research of type 2 diabetes .
|
-
- HY-172711A
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG3400-R6H4 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (R6H4). R6H4 can be used for pH responsive anticancer drug delivery purposes. DSPE-PEG3400-R6H4 can be used for drug delivery .
|
-
- HY-172711
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG2000-R6H4 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (R6H4). R6H4 can be used for pH responsive anticancer drug delivery purposes. DSPE-PEG2000-R6H4 can be used for drug delivery .
|
-
- HY-172712
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG3000-R6H4 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (R6H4). R6H4 can be used for pH responsive anticancer drug delivery purposes. DSPE-PEG3000-R6H4 can be used for drug delivery .
|
-
- HY-172710
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-R6H4 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (R6H4). R6H4 can be used for pH responsive anticancer drug delivery purposes. DSPE-PEG1000-R6H4 can be used for drug delivery .
|
-
- HY-P1404
-
|
|
Pim
|
Cancer
|
|
R8-T198wt is a cell-permeable carboxyl-terminal p27 Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase .
|
-
- HY-P2247
-
|
|
JNK
|
Cancer
|
|
JTP10-△-R9 TFA is a selective JNK2 peptide inhibitor, with an IC50 of 89 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3 .
|
-
- HY-P10107
-
|
|
Ras
|
Others
|
|
TAT-PAK18 R192A is an inactive Tat-Pak peptide. TAT-PAK18 R192A does not have any effect in the translocation of Rac1 triggered by any of the interrogated proteins .
|
-
- HY-P10474
-
|
|
Drug Isomer
|
Others
|
|
RYTVELA is a deriviative of the peptide antagonist of interleukin-1 receptor 1 (IL-1R1) d-(RYTVELA) (HY-P10353) that contains all L-amino acids .
|
-
- HY-I0786
-
|
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
(2S,4R)-Teneligliptin is a selective inhibitor of dipeptidyl peptidase IV (DPP-4). (2S,4R)-Teneligliptin increases the plasma concentration of active glucagon-like peptide-1 (GLP-1), which promotes insulin secretion in response to elevated blood glucose levels, exerting hypoglycemic activity. (2S,4R)-Teneligliptin is promising for research of type 2 diabetes .
|
-
- HY-P1205A
-
|
Melanin-concentrating hormone(human, mouse, rat) TFA
|
MCHR1 (GPR24)
|
Neurological Disease
|
|
MCH (human, mouse, rat) TFA is a potent peptide agonist of MCH-R and exhibits binding IC50 values of 0.3nM and 1.5 nM for MCH1R and MCH2R, respectively. MCH (human, mouse, rat) is a highly sensitive to MCH-2R in a CHO cell line and monitoring mobilization of intracellular calcium with FLIPR, exhibits functional activation EC50 values of 3.9 nM and 0.1nM for human MCH-1R and MCH-2R, respectively .
|
-
- HY-P10842
-
|
|
GLP Receptor
Akt
|
Metabolic Disease
Inflammation/Immunology
|
|
d-GLP-2 E33A is an agonist for the glucagon-like peptide 2 receptor (GLP-2R) with an EC50 of 414 nM. d-GLP-2 E33A can activate GLP-2R and increase the phosphorylation of AKT, but has no stimulative effect on GLP-1R. d-GLP-2 E33A can be used in the study of diseases such as intestinal malabsorption and inflammatory bowel diseases .
|
-
- HY-P10329
-
|
|
Fungal
|
Infection
|
|
KK14(R) is an analog of the de novo synthetic peptide KK14, which exhibits antifungal activity against Fusarium culmorum, Penicillium expansum and Aspergillus niger , with MICs of 6.25, 12.5 and 12.5 μg/mL, respecitvely. KK14(R) exhibits good heat- and pH-stability. KK14(R) exhibits cytotoxicity against cells Caco-2 and RAW264.7 .
|
-
- HY-117053
-
|
|
Neurokinin Receptor
|
Neurological Disease
|
|
ZM 253270 is a species-selective non-peptide NK-2 receptor (NK-2R) antagonist. ZM 253270 competitively inhibits the binding of [ 3H]NKA to native or cloned NK-2R from hamster bladder (Ki=2 nM), but has a weaker inhibitory effect (48-fold) on the binding of [ 3H]NKA to cloned human NK-2R .
|
-
- HY-P1453
-
|
|
STAT
|
Cancer
|
|
CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits Treg cell development .
|
-
- HY-P4156
-
|
|
mAChR
|
Neurological Disease
|
|
VLVNTFCDSCIPKTYWNLGY TFA is an antigenic peptide of M3 muscarinic receptor (M3R). VLVNTFCDSCIPKTYWNLGY TFA can be used in ELISA .
|
-
- HY-P990013
-
|
Glutazumab; GMA-102; GMA-105
|
GCGR
|
Metabolic Disease
|
|
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R .
|
-
- HY-P10843
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
R4K1 is a cell-permeable stapled peptide. R4K1 binds to the estrogen receptor (ER) α with high affinity and inhibits its interaction with coactivators. R4K1 can enter breast cancer cells to regulate gene transcription and inhibit cell proliferation. R4K1 can be used in the study of cancer .
|
-
- HY-P1453A
-
|
|
STAT
|
Cancer
|
|
CMD178 TFA is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits Treg cell development .
|
-
- HY-120308
-
|
SR140603
|
Neurokinin Receptor
|
Neurological Disease
|
|
(R)-Nolpitantium is the R-enantiomer of Nolpitantium (HY-108479). Nolpitantium (SR140333) is a potent, selective, competitive, non-peptide tachykinin NK1 receptor antagonist. Nolpitantium blocks the activation of rat thalamic neurons after nociceptive stimulation .
|
-
- HY-P0122
-
|
c(CRGDKGPDC)
|
Integrin
|
Cancer
|
|
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
|
-
- HY-P2706
-
|
|
Histamine Receptor
|
Endocrinology
|
|
Granuliberin R is a new mast cell degranulating peptide comes from amphibian, can be isolated from the skin of frog Rana rugosa. Granuliberin R is a dodecapeptide, can act on rat peritoneal mast cell to liberate granules and release histamine .
|
-
- HY-P4086
-
|
|
RABV
|
Infection
|
|
Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R), a chimeric peptide consisting of 29 amino acids, is synthesized by adding nona-arginine motif to the carboxy terminus of RVG (rabies virus glycoprotein). Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) is positively charged and able to bind negatively charged nucleic acids via charge interaction .
|
-
- HY-177295
-
|
LY3549492
|
GLP Receptor
Phosphodiesterase (PDE)
|
Metabolic Disease
|
|
Naperiglipron (LY3549492) (Example 2) is a Glucagon-like peptide 1 receptor (GLP-1R) agonist with an EC50 of 1.14 nM for hGLP-1R. Naperiglipron significantly decreases the level of blood glucose in GLP-1R knock-in mouse models. Naperiglipron inhibits PDE10A1 enzyme activity (IC50: 7.43 μM) with a weak hERG inhibitory activity. Naperiglipron can be used for type II diabetes mellitus (T2DM) and obesity research .
|
-
- HY-162838
-
|
|
Estrogen Receptor/ERR
|
Others
|
|
TCF199 is an allosteric stabilizer that stabilizes the 14-3-3/TAZ peptide interaction, binding to the 14-3-3ζ/E R α peptide and 14-3-3ζ/Chibby peptide. TCF199 has a Kd value of 122 μM for its interaction with 14-3-3/TAZ .
|
-
- HY-P5327
-
|
|
Bcl-2 Family
|
Others
|
|
r8 Bid BH3 is a biological active peptide. (The Bid BH3 is a pro-apoptotic member of the 'BH3-only' subset of BCL-2 family proteins that constitute a critical control point in apoptosis. r8BIDBH3 is lethal to human leukemia cell lines that expresse Bcl-2. The Bcl-2 antagonists may have the potential to be efficacious in cancer therapy. Poly-D-arginine (d-isomer as denoted by rrrrrrrr) is fused to the Bid BH3 peptide to facilitate cellular uptake of the peptide.)
|
-
- HY-P4403
-
|
(Z-Asp-Glu-Val-Asp)₂-Rhodamine 110
|
Fluorescent Dye
Apoptosis
Caspase
|
Others
|
|
Z-DEVD-R110 ((Z-Asp-Glu-Val-Asp)2-Rhodamine 110) is a fluorogenic caspase-3/7 substrate. Z-DEVD-R110 can be used to detect apoptosis. Z-DEVD-R110 is a rhodamine derivative with two four–amino acid (DEVD) peptides linked to the fuorophore .
|
-
- HY-P11293
-
|
|
Melanocortin Receptor
|
Cancer
|
|
DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .
|
-
- HY-P3542
-
|
|
GCGR
|
Metabolic Disease
|
|
Des His1, Glu8 Exendin-4 is a potent glucagon-like peptide-1 receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal .
|
-
- HY-P10055
-
|
PSMA-1
|
PSMA
|
Cancer
|
|
PSMA-1 is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells. PSMA-1 is selected and polyarginine sequences R6 or R9 were added at the C terminus to generate the CTPs. FITC labeling of the peptide with an aminohexanoic acid (Ahx) linker at the N terminus produced FITC-PSMA-1，to track PSMA binding on PCa cells .
|
-
- HY-P4146
-
|
BI 456906
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-145412
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
GLP-1 receptor agonist 7 (Compound 130b) is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 7 generates cAMP under the mediation of GLP-1R with an EC50 of ≤ 0.2 nM. GLP-1 receptor agonist 7 can be used to study diseases related to the GLP-1 receptor (particularly type 2 diabetes) .
|
-
- HY-P5419A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
WAAG-3R TFA is a biological active peptide. (Aggrecanases belong to the ADAMTS (A disintegrin and metalloprotease with thrombospondin motif) family of proteases. Aggrecanases cleave aggrecan, the major structural component of cartilage. Aggrecanase-1 (ADAMTS-4) is a major aggrecanase in human osteoarthritic cartilage. This FRET peptide was used in an ADAMTS-4 (Aggrecanase-1) and ADAMTS-5 (Aggrecanase-2) assay . (Ex/Em = 340/420 nm)
|
-
- HY-P4043
-
|
|
HBV
|
Infection
Inflammation/Immunology
|
|
Hepatitis b virus pre-s region (120-145) is a preS2 peptide that inhibits the binding of single-chain Fv fragment (scFv) or IgG to r-HBsAg .
|
-
- HY-P4146A
-
|
BI 456906 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P0165B
-
|
ITM077 acetate; R1583 acetate; BIM51077 acetate
|
GLP Receptor
|
Metabolic Disease
|
|
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an Ki value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .
|
-
- HY-146127
-
|
|
EGFR
|
Others
|
|
Grb2 SH2 domain inhibitor 1 is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
|
-
- HY-162339
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
BChE-IN-30 (compound (R)-37a) is a BChE inhibitor (IC50: 5 nM) with anti-inflammatory activity and low toxicity. BChE-IN-30 can improve cognitive deficits induced by scopolamine and Aβ1-42 peptide and can be used in the study of late-stage AD .
|
-
- HY-P1531
-
-
- HY-P1039
-
|
PHCVPRDLSWLDLEANMCLP
|
Raf
|
Cancer
|
|
R18 is a peptide antagonists of 14-3-3, with a KD of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .
|
-
- HY-146127A
-
|
|
Src
|
Others
|
|
Grb2 SH2 domain inhibitor 1 TFA is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
|
-
- HY-P5971A
-
|
|
Melanocortin Receptor
|
Metabolic Disease
|
|
TCMCB07 TFA, a cyclic nonapeptide peptide, is an orally active and brain-penetrant melanocortin receptor 4 (MC4R) antagonist. TCMCB07 TFA plays an important role in cachexia .
|
-
- HY-P1039A
-
|
PHCVPRDLSWLDLEANMCLP TFA
|
Raf
|
Cancer
|
|
R18 TFA is a peptide antagonists of 14-3-3, with a KD of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .
|
-
- HY-P1858A
-
|
|
CRFR
|
Cardiovascular Disease
Neurological Disease
Endocrinology
|
|
Urocortin III, mouse TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2 . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .
|
-
- HY-P1858
-
|
|
CRFR
|
Cardiovascular Disease
Neurological Disease
Endocrinology
|
|
Urocortin III, mouse is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2 . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .
|
-
- HY-P11086
-
|
|
Bacterial
|
Infection
|
|
c(R3W4V) is an antimicrobial peptide. c(R3W4V) has a relatively stable transmembrane structure. c(R3W4V) has IC50 values of 0.27 μM, 0.46 μM, and 0.05 μM for E. coli, S. aureus, and B. subtilis, respectively .
|
-
- HY-14789R
-
|
|
GnRH Receptor
Nuclear Factor of activated T Cells (NFAT)
|
Endocrinology
Cancer
|
|
(R)-Elagolix (Standard) is the analytical standard of (R)-Elagolix. This product is intended for research and analytical applications. Elagolix is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (KD = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .
|
-
- HY-P4899
-
|
|
Beta-secretase
|
Neurological Disease
|
|
RE (EDANS) EVNLDAEFK (DABCYL) R is an EDANS and DABCYL double-labeled peptide，serves as a fluorescent substrate for BACE1(Em=360nm，Ex=528nm). RE (EDANS) EVNLDAEFK (DABCYL) R can be used for BACE1 activity measurement and the enzyme activity level is directly proportional to the fluorescence reaction .
|
-
- HY-P2191
-
|
|
Kisspeptin Receptor
|
Endocrinology
|
|
KISS1-305, the Metastin/Kisspeptin analog, is a prototype peptide and a chemical probe. KISS1-305 has suboptimal KISS1R agonistic activity, and resists plasma protease degradation .
|
-
- HY-P3375
-
|
IBI-362; LY-3305677; OXM-3
|
GCGR
GLP Receptor
|
Metabolic Disease
|
|
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .
|
-
- HY-110196
-
|
|
Histone Methyltransferase
|
Others
|
|
(S)-PFI-2 hydrochloride is an inhibitor of lysine methyltransferase SETD7 and is approximately 500-fold more active than its enantiomer (R)-PFI-2. (R)-PFI-2 is a cofactor-dependent and substrate-competitive inhibitor. (R)-PFI-2 can occupy the substrate peptide binding groove of SETD7 (including the catalytic lysine binding channel) and interact with the cofactor The donor methyl group is in direct contact. However, (S)-PFI-2 was not observed to have the same interaction as (R)-PFI-2 .
|
-
- HY-W006886
-
|
|
Amino Acid Derivatives
|
Others
|
|
Fmoc-(R)-2-(7-octenyl)Ala-OH is an amino acid derivative with an Fmoc protecting group that can be used to synthesize inhibitor peptides that combinatorially inactivate ErbB1, ErbB2, and ErbB3 .
|
-
- HY-128941
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker .
|
-
- HY-P10815
-
|
|
Apoptosis
Calcium Channel
|
Others
|
|
IP3RCYT is an IP3R inhibitory peptide, which can inhibit the binding of cytochrome C to IP3R with an IC50 about 100 nM. IP3RCYT regulates calcium signaling within cells. P3RCYT inhibits apoptosis in HeLa and Jurkat cells treated with Staurosporine (HY-15141) or Membrane-bound Fas ligand (FasL) .
|
-
- HY-P3375A
-
|
IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA
|
GCGR
GLP Receptor
|
Metabolic Disease
|
|
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .
|
-
- HY-P5971
-
|
Mifomelatide
|
Melanocortin Receptor
|
Metabolic Disease
|
|
TCMCB07, a cyclic nonapeptide peptide, is an orally active and brain-penetrant melanocortin receptor 4 (MC4R) antagonist. TCMCB07 plays an important role in cachexia. TCMCB07 has potential transport capabilities .
|
-
- HY-P1074
-
SNX-482
1 Publications Verification
|
Calcium Channel
|
Neurological Disease
|
|
SNX-482, a peptide, is a potent, high affinity, selective and voltage-dependent R-type CaV2.3 channel blocker with an IC50 of 30 nM. SNX-482 has antinociceptive effect .
|
-
- HY-P2516
-
|
|
Tau Protein
|
Neurological Disease
|
|
Tau Peptide (275-305) (Repeat 2 domain) is the Alzheimer's Tau fragment R2, corresponding to the second repeat unit of the microtubule-binding domain, which is believed to be pivotal to the biochemical properties of full tau protein. Tau Peptide (275-305) specifically coordinates with group IIB metal ions (Zn²⁺, Cd²⁺, Hg²⁺), which can induce their conformational changes and significantly promote their pathological accumulation. Tau Peptide (275-305) can be used to study the role of heavy metals in neurodegenerative diseases .
|
-
- HY-P10256A
-
|
|
Kisspeptin Receptor
PKA
PKC
|
Endocrinology
|
|
Kiss2 peptide acetate is the acetate form of Kiss2 pepride (HY-P10256). Kiss2 peptide acetate is a positive regulator of reproduction. Kiss2 peptide acetate binds with its cognate receptor Kiss2R (GPR54) in COS-7 cells, activates PKA and PKC signaling pathways through Gas and Gaq proteins, and thus enhances the activity of cAMP response element-dependent luciferase (CRE-luc) and serum response element-dependent luciferase (SRE-luc) .
|
-
- HY-P11089
-
|
|
MHC
|
Cancer
|
|
TP53 neoepitope is a high-affinity antigenic peptide targeting HLA-A. TP53 neoepitope can triggers CD8 + T cell-mediated killing of TP53-mutant tumor cells. TP53 neoepitope is promising for research of solid tumors harboring TP53 hotspot mutations (e.g., R175H, R273H) .
|
-
- HY-106203B
-
|
(R)-SSR-125543
|
CFTR
|
Metabolic Disease
|
|
(R)-Crinecerfont is the R-enantiomer of Crinecerfont (HY-106203). Crinecerfont (SSR-125543) is a potent, orally active, non-peptide CRF1 receptor antagonist. Crinecerfont can be used for Classic congenital adrenal hyperplasia (CAH) research. Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .
|
-
- HY-P3873
-
-
- HY-172495
-
|
|
Liposome
Integrin
|
Cancer
|
|
DSPE-PEG3000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3000-iRGD can be used for drug delivery .
|
-
- HY-172493
-
|
|
Liposome
Integrin
|
Cancer
|
|
DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery .
|
-
- HY-172494
-
|
|
Liposome
Integrin
|
Cancer
|
|
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for drug delivery .
|
-
- HY-P10256
-
|
|
Kisspeptin Receptor
PKA
PKC
|
Endocrinology
|
|
Kiss2 peptide is a positive regulator of reproduction. Kiss2 peptide binds with its cognate receptor Kiss2R (GPR54) in COS-7 cells, activates PKA and PKC signaling pathways through Gas and Gaq proteins, and thus enhances the activity of cAMP response element-dependent luciferase (CRE-luc) and serum response element-dependent luciferase (SRE-luc) .
|
-
- HY-172494A
-
|
|
Liposome
Integrin
|
Cancer
|
|
DSPE-PEG3400-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3400-iRGD can be used for drug delivery .
|
-
- HY-P10975
-
|
|
SARS-CoV
Influenza Virus
Enterovirus
|
Infection
|
|
P9R is an antiviral peptide. P9R has broad-spectrum antiviral activities against the coronaviruses (SARS-CoV-2, MERS-CoV and SARS-CoV), A(H1N1)pdm09, A(H7N9) virus, and rhinovirus. P9R directly binds to viruses and inhibits virus-host endosomal acidification. P9R significantly protects mice from A(H1N1)pdm09 infection without generating drug-resistant virus. P9R can be used for pH-dependent respiratory viruses research .
|
-
- HY-P10018
-
|
SAR425899
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes .
|
-
- HY-E70730
-
|
|
IGF-1R
|
Metabolic Disease
|
|
The whole IGF axis constitutes an interactive network composed of the peptide-ligands IGF1, IGF2 and insulin, and the receptors IGF1R, IGF2R and insulin receptor (INSR) as IGF binding proteins (IGFBPs). The INSR itself appears in two isoforms, INSRA and INSRB differing in 12 amino acids encoded by exon 11. INSR Recombinant Human Active Protein Kinase is a recombinant INSR protein that can be used to study INSR-related functions .
|
-
- HY-P5247A
-
|
PTP20 TFA
|
Melanocortin Receptor
Sirtuin
|
Metabolic Disease
Inflammation/Immunology
|
|
Palmitoyl tetrapeptide-20 (PTP20) TFA is a biomimetic peptide agonist of α-MSH. Palmitoyl tetrapeptide-20 TFA promotes hair pigmentation and delays hair graying by activating the MC1-R pathway (AC50: 0.16 nM), enhancing catalase activity to reduce H2O2 accumulation, and upregulating SIRT1 activity. Palmitoyl tetrapeptide-20 TFA can be used in research on preventing hair loss and improving hair graying .
|
-
- HY-P5247
-
|
PTP20
|
Melanocortin Receptor
Sirtuin
|
Metabolic Disease
Inflammation/Immunology
|
|
Palmitoyl tetrapeptide-20 (PTP20) is a biomimetic peptide agonist of α-MSH. Palmitoyl tetrapeptide-20 promotes hair pigmentation and delays hair graying by activating the MC1-R pathway (AC50: 0.16 nM), enhancing catalase activity to reduce H2O2 accumulation, and upregulating SIRT1 activity. Palmitoyl tetrapeptide-20 can be used in research on preventing hair loss and improving hair graying .
|
-
- HY-P5645
-
LEAP-2
1 Publications Verification
Human liver expressed antimicrobial Peptide-2
|
GHSR
Interleukin Related
IFNAR
TNF Receptor
Bacterial
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
LEAP-2 (Human liver expressed antimicrobial peptide-2) is a GHS-R1a antagonist, with an IC50 of 6.0 nM. LEAP-2 suppresses the orexigenic effect of ghrelin. LEAP-2 attenuates ghrelin-induced growth hormone (GH) release and reduces basal food intake. LEAP-2 exhibits antimicrobial activity against microbial model organisms. LEAP-2 can be used for the study of obesity and infection .
|
-
- HY-P10358A
-
|
|
Calcium Channel
|
Neurological Disease
|
|
TAT-CBD3A6K acetate, is a modified TAT-CBD3 peptide. TAT-CBD3A6K acetate reduces T- and R-type voltage-dependent calcium currents in dorsal root ganglion (DRG) neurons. TAT-CBD3A6K acetate shows anti-nociceptive effects in a model of AIDS-induced peripheral neuropathy by preventing CRMP-2-mediated enhancement of T- and R-type calcium channel function .
|
-
- HY-P3736
-
|
MP-2
|
Interleukin Related
|
Cancer
|
|
Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research .
|
-
- HY-P10358
-
|
|
Calcium Channel
|
Neurological Disease
|
|
TAT-CBD3A6K, is a modified TAT-CBD3 peptide. TAT-CBD3A6K reduces T- and R-type voltage-dependent calcium currents in dorsal root ganglion (DRG) neurons. TAT-CBD3A6K shows anti-nociceptive effects in a model of AIDS-induced peripheral neuropathy by preventing CRMP-2-mediated enhancement of T- and R-type calcium channel function .
|
-
- HY-E70574
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Trypsin/Lys-C complex protease (MS grade) combines Trypsin and Lys-C, two recombinant proteases, to achieve efficient peptide bond hydrolysis. Trypsin specifically cleaves the C-terminal peptide bonds of arginine (R) and lysine (K), while Lys-C specifically cleaves the C-terminal peptide bonds of lysine (K). This combination overcomes issues such as the slower digestion rate of lysine and arginine by rTrypsin, PTM changes on lysine, or hydrophobic C-termini (such as proline) that can lead to missed cleavage. Trypsin/Lys-C complex protease (MS grade) can be used to process complex protein samples that are difficult to enzymatically digest. Trypsin/Lys-C complex protease (MS grade) can be used for protein characterization, single-cell proteomics and large cohort proteomics studies.
|
-
- HY-P10827
-
|
|
Complement System
|
Inflammation/Immunology
|
|
PIC1 PA, a 15 amino-acid peptide, is a potent PIC1 analog that inhibits classical pathway mediated complement activation. PIC1 PA functionally disrupts the C1s-C1r-C1r-C1s/MASPs interaction with collagen-like region (CLR) of C1q/MBL, respectively. PIC1 PA specifically binds to the CLR of C1q and bounds to purified C1q with a mean equilibrium dissociation constant (KD) of 33.3 nM .
|
-
- HY-150700
-
|
|
ERK
|
Metabolic Disease
|
|
RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome .
|
-
- HY-103277A
-
|
|
Bombesin Receptor
|
Neurological Disease
Metabolic Disease
|
|
BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca 2+ release .
|
-
- HY-103277
-
|
|
Bombesin Receptor
|
Neurological Disease
Metabolic Disease
|
|
BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca 2+ release .
|
-
- HY-P10489
-
|
|
Kisspeptin Receptor
|
Cancer
|
|
Kisspeptin-14 human is a peptide hormone encoded by the KiSS-1 gene. Kisspeptin-14 human, along with several other similar peptide hormones, is produced from a common precursor protein by cleavage by different proteases. Kisspeptin-14 human is an endogenous ligand of KISS1R. Kisspeptin-14 human has the same receptor binding efficiency and potency as full-length kisspeptin. Kisspeptin-14 human binds to its receptor GPR54 and is able to activate this G protein-coupled receptor and activate multiple intracellular signaling pathways. Kisspeptin-14 human can be used to study reproductive development and tumor metastasis .
|
-
- HY-P11312
-
|
|
Neurokinin Receptor
|
Neurological Disease
|
|
[S5K, F6Y, L9mL, M10Mox] neurokinin A (4–10) is a neuropeptide A analog and a peptide fragment of HY-P10746. [S5K, F6Y, L9mL, M10Mox] neurokinin A (4–10) is highly selective for mouse tachykinin receptors and human tachykinin receptor NK1R and has an in vivo half-life of 10.3 hours in mice .
|
-
![[S5K, F6Y, L9mL, M10Mox] neurokinin A (4–10)](//file.medchemexpress.eu/product_pic/hy-p11312.gif)
- HY-P0097A
-
|
Melanostatine-5 acetate salt
|
Melanocortin Receptor
|
Metabolic Disease
Endocrinology
Cancer
|
|
Nonapeptide-1 (Melanostatine-5) acetate salt, a peptide hormone, is a selective antagonist of MC1R (Ki: 40 nM). Nonapeptide-1 acetate salt is a competitive α-MSH antagonist that potently inhibits intracellular cAMP and melanosome dispersion induced by α-MSH in melanocytes (IC50: 2.5 nM and 11 nM, respectively). Nonapeptide-1 acetate salt inhibits melanin synthesis, and can be used in the research of skin pigmentation and regulation of steroid production in the adrenal gland, skin cancer .
|
-
- HY-P0097
-
|
Melanostatine-5
|
Melanocortin Receptor
|
Metabolic Disease
Endocrinology
Cancer
|
|
Nonapeptide-1 (Melanostatine-5), a peptide hormone, is a selective antagonist of MC1R (Ki: 40 nM). Nonapeptide-1 is a competitive α-MSH antagonist that potently inhibits intracellular cAMP and melanosome dispersion induced by α-MSH in melanocytes (IC50: 2.5 nM and 11 nM, respectively). Nonapeptide-1 inhibits melanin synthesis, and can be used in the research of skin pigmentation and regulation of steroid production in the adrenal gland, skin cancer .
|
-
- HY-P1110
-
AF12198
4 Publications Verification
|
Interleukin Related
|
Inflammation/Immunology
|
|
AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 µM) or the murine type I receptor (IC50>200 µM). AF12198 inhibits IL-1-induced IL-8 production (IC50=25 nM) and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression (IC50=9 nM) in vitro. AF12198 has anti-inflammatory activities and blocks responses to IL-1 in vivo .
|
-
- HY-116216
-
|
|
Bombesin Receptor
|
Cancer
|
|
PD 168368 is a potent, competitive, and selective neuromedin B receptor (NMB-R) antagonist with the Ki of 15–45 nM . PD 168368 is neuromedin B receptor (NMBR; IC50=96 nM) / gastrin-releasing peptide receptor (GRPR IC50=3500 nM) antagonist . PD 168368 also is a mixed FPR1/FPR2/FPR3 agonist with EC50s of 0.57, 0.24, and 2.7 nM, respectively .
|
-
- HY-13948BS
-
|
Angiotensin II-13C6,15N TFA; Ang II-13C6,15N TFA; DRVY(I-13C6,15N)HPF TFA
|
Isotope-Labeled Compounds
|
Cancer
|
|
Angiotensin II human- 13C6, 15N TFA (Ang II- 13C6, 15N TFA) is 13C- and 15N-labeled Angiotensin II human (TFA) (HY-13948B). Angiotensin II human (Angiotensin II) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions .
|
-
- HY-13948
-
|
Angiotensin II; Ang II; DRVYIHPF
|
Angiotensin Receptor
Apoptosis
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Angiotensin II (Angiotensin II) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human also induces apoptosis. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
|
-
- HY-13948A
-
|
Angiotensin II acetate; Ang II acetate; DRVYIHPF acetate
|
Angiotensin Receptor
Apoptosis
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Angiotensin II human (Angiotensin II) acetate is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human acetate plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human acetate stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human acetate induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human acetate also induces apoptosis. Angiotensin II human acetate induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
|
-
- HY-P3019
-
|
|
CRFR
|
Cardiovascular Disease
Neurological Disease
Endocrinology
|
|
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) selectively binds to type 2 CRF receptors with Ki values of 13.5, 21.7, and >100 nM for mCRF2β, rCRF2α, and hCRF1, respectively. Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .
|
-
- HY-13948B
-
|
Angiotensin II TFA; Ang II TFA; DRVYIHPF TFA
|
Angiotensin Receptor
Apoptosis
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Angiotensin II human (Angiotensin II) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human TFA induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human TFA also induces apoptosis. Angiotensin II human TFA induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
|
-
- HY-P1925A
-
|
|
PI3K
Reactive Oxygen Species (ROS)
Apoptosis
|
Cancer
|
|
GO-203 TFA is a potent MUC1-C oncoprotein inhibitor. GO-203 TFA is an all D-amino acid peptide that consists of a poly-R transduction domain linked to a CQCRRKN motif that binds to the MUC1-C cytoplasmic tail and blocks MUC1-C homodimerization. GO-203 TFA downregulates TIGAR (TP53-induced glycolysis and apoptosis regulator) protein synthesis by inhibiting the PI3K-AKT-S6K1 pathway. GO-203 TFA induces the production of ROS and loss of mitochondrial transmembrane potential. GO-203 TFA inhibits the growth of colon cancer cells in vitro and as xenografts in nude mice .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-172276A
-
|
|
Drug Delivery
|
|
DSPE-PEG2000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG2000-R8 can be used for drug delivery .
|
-
- HY-172276
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG1000-R8 can be used for drug delivery .
|
-
- HY-172276C
-
|
|
Drug Delivery
|
|
DSPE-PEG3400-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG3400-R8 can be used for drug delivery .
|
-
- HY-172276B
-
|
|
Drug Delivery
|
|
DSPE-PEG5000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG5000-R8 can be used for drug delivery .
|
-
- HY-172277B
-
|
|
Drug Delivery
|
|
DSPE-PEG5000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG5000-R9 can be used for drug delivery .
|
-
- HY-172277A
-
|
|
Drug Delivery
|
|
DSPE-PEG2000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG2000-R9 can be used for drug delivery .
|
-
- HY-172277C
-
|
|
Drug Delivery
|
|
DSPE-PEG3400-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG3400-R9 can be used for drug delivery .
|
-
- HY-172277
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG1000-R9 can be used for drug delivery .
|
-
- HY-172272B
-
|
|
Drug Delivery
|
|
DSPE-PEG5000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-172272A
-
|
|
Drug Delivery
|
|
DSPE-PEG2000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-172272
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-172272C
-
|
|
Drug Delivery
|
|
DSPE-PEG3400-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-158077
-
|
(R)-tetraMe-DOTA
|
Chelators
|
|
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.
|
-
- HY-172711A
-
|
|
Drug Delivery
|
|
DSPE-PEG3400-R6H4 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (R6H4). R6H4 can be used for pH responsive anticancer drug delivery purposes. DSPE-PEG3400-R6H4 can be used for drug delivery .
|
-
- HY-172711
-
|
|
Drug Delivery
|
|
DSPE-PEG2000-R6H4 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (R6H4). R6H4 can be used for pH responsive anticancer drug delivery purposes. DSPE-PEG2000-R6H4 can be used for drug delivery .
|
-
- HY-172712
-
|
|
Drug Delivery
|
|
DSPE-PEG3000-R6H4 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (R6H4). R6H4 can be used for pH responsive anticancer drug delivery purposes. DSPE-PEG3000-R6H4 can be used for drug delivery .
|
-
- HY-172710
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-R6H4 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (R6H4). R6H4 can be used for pH responsive anticancer drug delivery purposes. DSPE-PEG1000-R6H4 can be used for drug delivery .
|
-
- HY-172495
-
|
|
Drug Delivery
|
|
DSPE-PEG3000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3000-iRGD can be used for drug delivery .
|
-
- HY-172493
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery .
|
-
- HY-172494
-
|
|
Drug Delivery
|
|
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for drug delivery .
|
-
- HY-172494A
-
|
|
Drug Delivery
|
|
DSPE-PEG3400-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3400-iRGD can be used for drug delivery .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4111
-
|
|
CXCR
|
Cancer
|
|
Peptide R, a cyclic peptide, is a specific CXCR4 antagonist. Peptide R shows outstanding capacities to profoundly remodel the tumor stroma. Peptide R has the potential for tumor research .
|
-
- HY-P4111A
-
|
|
CXCR
|
Cancer
|
|
Peptide R (TFA) is a synthetic and specific CXCR4 antagonist. Peptide R (TFA) shows outstanding capacities to remodel the tumor stroma. Peptide R (TFA) can be used for solid tumor (glioblastoma, etc.) research .
|
-
- HY-P0133B
-
|
Nona-L-arginine acetate; Peptide R9 acetate
|
Ser/Thr Protease
|
Neurological Disease
|
|
(Arg)9 (Nona-L-arginine) acetate is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 acetate has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model .
|
-
- HY-P0133A
-
|
Nona-L-arginine TFA; Peptide R9 TFA
|
Ser/Thr Protease
|
Neurological Disease
|
|
(Arg)9 (Nona-L-arginine) TFA is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 TFA has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model .
|
-
- HY-P10510A
-
-
- HY-P10918
-
|
|
Peptides
|
Inflammation/Immunology
|
|
F11R peptide TFA is a F11 receptor molecule. F11R peptide TFA inhibits anti-F11R antibody-induced platelet aggregation, and inhibits the adhesion of platelets to cytokine (TNFα and INF-γ)-inflammed endothelial cells. F11R peptide TFA can be used for research of atherosclerotic plaques and associated thrombotic disease .
|
-
- HY-P11011
-
|
Pep R54; CXCR4 antagonist Peptide 19
|
CXCR
|
Cancer
|
|
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC50=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .
|
-
- HY-P10973
-
|
|
CXCR
ERK
|
Cancer
|
|
Peptide R analogue 10 (compound 10) is an analog of the CXCR4 antagonist peptide Peptide R (HY-P4111) with stronger antagonistic potency, specificity and plasma stability. Peptide R analogue 10 can inhibit CXCL12-mediated cell migration, ERK phosphorylation and CXCR4 internalization. Peptide R analogue 10 can be used in the study of CXCR4 overexpressing leukemia and colon cancer .
|
-
- HY-P0133
-
|
Nona-L-arginine; Peptide R9
|
Ser/Thr Protease
|
Neurological Disease
|
|
(Arg)9 (Nona-L-arginine) is a cell-penetrating peptide (CPP) made up of 9 arginine residues, which is an inhibitor of serine endoprotease Furin. (Arg)9 has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model .
|
-
- HY-P5397
-
|
|
Peptides
|
Others
|
|
IRBP derived peptide, R16 is a biological active peptide. (R16 is an IRBP (Interphotoreceptor retinoid binding protein) derived peptide. Photoreceptor cell protein is capable of inducing an experimental autoimmune uveitis (EAU) in susceptible animal strains.)
|
-
- HY-P5397A
-
|
|
Peptides
|
Others
|
|
IRBP derived peptide, R16 is a biological active peptide. (R16 is an IRBP (Interphotoreceptor retinoid binding protein) derived peptide. Photoreceptor cell protein is capable of inducing an experimental autoimmune uveitis (EAU) in susceptible animal strains.)
|
-
- HY-P10510
-
-
- HY-P10723
-
-
- HY-P3918
-
|
|
p38 MAPK
|
Others
|
|
EGF-R (661-681) T669 Peptide is a MAPK substrate that can used to measure MAPK catalytic activity .
|
-
- HY-P3291
-
|
ZP7570
|
GCGR
|
Metabolic Disease
|
|
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .
|
-
- HY-P11453
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
R9H6 is a peptide containing nine arginine peptides and six histidine peptides. The LP(R9H6)m nanocomplex containing R9H6 exhibits high efficiency in mRNA delivery. R9H6 can be used in the research of anaplastic thyroid cancer .
|
-
- HY-P3506
-
|
LY3437943
|
GCGR
GLP Receptor
|
Metabolic Disease
|
|
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .
|
-
- HY-P3506B
-
|
LY3437943 acetate
|
GCGR
GLP Receptor
|
Metabolic Disease
|
|
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .
|
-
- HY-P3506A
-
|
LY3437943 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .
|
-
- HY-W018847
-
|
|
Peptides
|
Others
|
|
Fmoc-(R)-2-(pentenyl)Ala-OH is a peptide intermediate and can be used in peptide synthesis.
|
-
- HY-P10116
-
|
APTscr-9R
|
STAT
|
Others
|
|
APTSTAT3-9R, scrambled (APTscr-9R) is a control peptide that forms a structure similar to that of APTSTAT3-9R but possesses a scrambled sequence in the target-binding region .
|
-
- HY-P5329
-
|
|
NADPH Oxidase
|
Others
|
|
r8-Gly-Noxa A BH3 is a biological active peptide. (This cell permeable peptide is derived from the BH3 domain (a death domain) of Noxa A, amino acid residues 17 to 36. Eight D-Arginine residues and a Glycine linker residue are added to the amino terminal of the peptide.)
|
-
- HY-P5438
-
|
|
Btk
c-Kit
FAK
FLT3
Insulin Receptor
|
Others
|
|
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)
|
-
- HY-P11031
-
|
|
Fungal
|
Infection
|
|
CotH3 peptide is a functional peptide unique to Mucorales that binds to the host GRP78 receptor and allows them to invade endothelial cells. CotH3 peptide–targeted monoclonal antibodies protect immunosuppressed mice from mucormycosis caused by R. delemar and other Mucorales. CotH3 peptide also synergizes with antifungal drugs to protect mice with diabetic ketoacidosis (DKA) from R. delemar infection .
|
-
- HY-P10392AF
-
|
|
Wnt
β-catenin
|
Cancer
|
|
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
|
-
- HY-P1285
-
|
Con-R
|
iGluR
|
Neurological Disease
|
|
Conantokin R (Con-R) is an NMDA receptor peptide antagonist with an IC50 of 93 nM. Conantokin R binds Zn 2+ and Mg 2+ with Kds of 0.15 μM and 6.5 μM, respectively. Conantokin R shows anticonvulsant activity .
|
-
- HY-P3790
-
|
|
Peptides
|
Others
|
|
T-F-Q-A-Y-P-L-R-E-A is a peptide. T-F-Q-A-Y-P-L-R-E-A can be used for the research of various biochemical .
|
-
- HY-P11043
-
|
|
GLP Receptor
Neuropeptide Y Receptor
Arrestin
|
Metabolic Disease
|
|
GEP44 is a peptide biased triple agonist targeting Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R). GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .
|
-
- HY-P10392
-
|
|
β-catenin
Wnt
|
Cancer
|
|
aStAx-35R, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells .
|
-
- HY-P5527F
-
|
|
Peptides
|
Others
|
|
FAM-CSKtide is a biological active peptide. (This is a FAM labeled peptide substrate (Abs/Em = 494/521 nm) for C-terminal Src kinase (Csk) and many other kinases such as Axl, cKit, ERBB4, Fes, Flt3, IGF-1 R, MET, MUSK, PYK2, Ret, TIE2, TrkA, VEGF-R1 and VEGF-R2.)
|
-
- HY-P10168
-
|
|
Phosphatase
|
Others
|
|
11R-CaN-CON is a control inactive peptide and can be used as a negative control for 11R-CaN-AID (HY-P10167) .
|
-
- HY-P0242
-
-
- HY-P10302A
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC50 is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC50 is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
- HY-P2282
-
|
|
STAT
|
Cancer
|
|
APTSTAT3-9R, a specific STAT3-binding peptide, inhibits STAT3 activation and downstream signaling by specifically blocking STAT3 phosphorylation. APTSTAT3-9R exerts antiproliferative effects and antitumor activity .
|
-
- HY-P0242A
-
-
- HY-P10392B
-
|
|
β-catenin
Wnt
|
Cancer
|
|
aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells .
|
-
- HY-P11286
-
|
|
Peptides
|
Cancer
|
|
A7RC is a multifunctional peptide used in tumor-targeted therapy, with Cysteine added to the C-terminal of the A7R peptide (sequence: ATWLPPR). A7R (HY-P1663) is a ligand of the NRP-1 receptor, regulating intracellular signal transduction related to tumor vascularization and tumor growth .
|
-
- HY-P1504
-
-
- HY-18678A
-
|
PT-141 Acetate
|
Melanocortin Receptor
|
Endocrinology
|
|
Bremelanotide Acetate (PT-141 Acetate), a synthetic peptide analogue of α-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R for the treatment of sexual dysfunction .
|
-
- HY-45894
-
|
Semaglutide side chain
|
GLP Receptor
|
Metabolic Disease
|
|
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is an intermediate in the synthesis of the glucagon-like peptide 1 receptor (GLP-1R) agonist Semaglutide (HY-114118).
|
-
- HY-P11044
-
|
|
GCGR
Neuropeptide Y Receptor
|
Metabolic Disease
|
|
GEP12 is a GLP-1R/Y1-R/Y2-R tri-receptor agonist peptide with an EC50 of 17.3 nM and an IC50 of 19.2 nM for receptor binding. GEP12 may promote glycemic control and weight loss .
|
-
- HY-P10166
-
|
|
Peptides
|
Others
|
|
MLCK Peptide, control is a myosin light-chain
kinase. Adding MLCK peptide to permeabilized L15 cells dramatically decreased
IICR. MLCK peptide caused a reduction in the extent of IICR with no change in
the affinity of IP3 for the IP3R .
|
-
- HY-P1504A
-
-
- HY-P10830
-
-
- HY-P11285
-
|
Long acting GIPRA-1
|
Insulin Receptor
|
Metabolic Disease
|
|
LAGIPRA peptide is a long-acting GIP1R agonist. LAGIPRA peptide enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide has the potential for the research of type 2 diabetes .
|
-
- HY-P11245
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
NN1213 (Peptide 21), a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with an EC50 of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 significantly reduces appetite in rat and dog models. NN1213 can be used for antiobesity research .
|
-
- HY-P11245A
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
NN1213 acetate (Peptide 21), a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with an EC50 of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 acetate significantly reduces appetite in rat and dog models. NN1213 acetate can be used for antiobesity research .
|
-
- HY-P10302
-
|
|
GLP Receptor
Insulin Receptor
|
Metabolic Disease
|
|
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
- HY-P3539
-
|
|
GCGR
|
Neurological Disease
Endocrinology
|
|
Exendin-4 (3-39) is a peptide. Exendin-4 (3-39) is a truncated form of Exendin-4 (HY-13443) that lacks the first two amino acids. Exendin-4 is a potent Glucagon-like peptide-1 receptor (GLP-1r) agonist. Exendin-4 (3-39) and Exendin-4 can be used for the research of diabetic and hypothalamic-pituitary-adrenal (HPA) axis .
|
-
- HY-P0264A
-
|
Avexitide acetate
|
GLP Receptor
|
Metabolic Disease
|
|
Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research .
|
- HY-P3226
-
|
|
IGF-1R
|
Metabolic Disease
|
|
JB-1, an IGF-1 peptide analog, is a selective and potent IGF-1R antagonist. JB-1 competes with IGF-1 by binding the IGF-1 receptor. JB-1 prevents the autophosphorylation of IGF-1R, and has no activity in IGF-II .
|
- HY-P1205
-
|
Melanin-concentrating hormone(human, mouse, rat)
|
MCHR1 (GPR24)
|
Neurological Disease
|
|
MCH (human, mouse, rat) is a potent peptide agonist of MCH-R and exhibits binding IC50 values of 0.3nM and 1.5 nM for MCH1R and MCH2R, respectively. MCH (human, mouse, rat) is a highly sensitive to MCH-2R in a CHO cell line and monitoring mobilization of intracellular calcium with FLIPR, exhibits functional activation EC50 values of 3.9 nM and 0.1nM for human MCH-1R and MCH-2R, respectively .
|
- HY-P11285A
-
|
Long acting GIPRA-1 TFA
|
Insulin Receptor
|
Metabolic Disease
|
|
LAGIPRA peptide TFA is a long-acting GIP1R agonist. LAGIPRA peptide TFA enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide TFA has the potential for the research of type 2 diabetes .
|
- HY-P1404
-
|
|
Pim
|
Cancer
|
|
R8-T198wt is a cell-permeable carboxyl-terminal p27 Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase .
|
- HY-P2247
-
|
|
JNK
|
Cancer
|
|
JTP10-△-R9 TFA is a selective JNK2 peptide inhibitor, with an IC50 of 89 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3 .
|
- HY-P10107
-
|
|
Ras
|
Others
|
|
TAT-PAK18 R192A is an inactive Tat-Pak peptide. TAT-PAK18 R192A does not have any effect in the translocation of Rac1 triggered by any of the interrogated proteins .
|
- HY-P10474
-
|
|
Drug Isomer
|
Others
|
|
RYTVELA is a deriviative of the peptide antagonist of interleukin-1 receptor 1 (IL-1R1) d-(RYTVELA) (HY-P10353) that contains all L-amino acids .
|
- HY-P5364
-
|
|
Peptides
|
Others
|
|
B8R 20-27 is a biological active peptide. (This is amino acids 20 to 27 fragment of B8R, a vaccinia virus (VV) gene that encodes a secreted protein related to gamma interferon receptor. B8R binding to IFN-g neutralizes its antiviral activity.)
|
- HY-P1205A
-
|
Melanin-concentrating hormone(human, mouse, rat) TFA
|
MCHR1 (GPR24)
|
Neurological Disease
|
|
MCH (human, mouse, rat) TFA is a potent peptide agonist of MCH-R and exhibits binding IC50 values of 0.3nM and 1.5 nM for MCH1R and MCH2R, respectively. MCH (human, mouse, rat) is a highly sensitive to MCH-2R in a CHO cell line and monitoring mobilization of intracellular calcium with FLIPR, exhibits functional activation EC50 values of 3.9 nM and 0.1nM for human MCH-1R and MCH-2R, respectively .
|
- HY-P10842
-
|
|
GLP Receptor
Akt
|
Metabolic Disease
Inflammation/Immunology
|
|
d-GLP-2 E33A is an agonist for the glucagon-like peptide 2 receptor (GLP-2R) with an EC50 of 414 nM. d-GLP-2 E33A can activate GLP-2R and increase the phosphorylation of AKT, but has no stimulative effect on GLP-1R. d-GLP-2 E33A can be used in the study of diseases such as intestinal malabsorption and inflammatory bowel diseases .
|
- HY-P10329
-
|
|
Fungal
|
Infection
|
|
KK14(R) is an analog of the de novo synthetic peptide KK14, which exhibits antifungal activity against Fusarium culmorum, Penicillium expansum and Aspergillus niger , with MICs of 6.25, 12.5 and 12.5 μg/mL, respecitvely. KK14(R) exhibits good heat- and pH-stability. KK14(R) exhibits cytotoxicity against cells Caco-2 and RAW264.7 .
|
- HY-P1453
-
|
|
STAT
|
Cancer
|
|
CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits Treg cell development .
|
- HY-P4156
-
|
|
mAChR
|
Neurological Disease
|
|
VLVNTFCDSCIPKTYWNLGY TFA is an antigenic peptide of M3 muscarinic receptor (M3R). VLVNTFCDSCIPKTYWNLGY TFA can be used in ELISA .
|
- HY-P10843
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
R4K1 is a cell-permeable stapled peptide. R4K1 binds to the estrogen receptor (ER) α with high affinity and inhibits its interaction with coactivators. R4K1 can enter breast cancer cells to regulate gene transcription and inhibit cell proliferation. R4K1 can be used in the study of cancer .
|
- HY-P1453A
-
|
|
STAT
|
Cancer
|
|
CMD178 TFA is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits Treg cell development .
|
- HY-P0122
-
|
c(CRGDKGPDC)
|
Integrin
|
Cancer
|
|
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
|
- HY-P2706
-
|
|
Histamine Receptor
|
Endocrinology
|
|
Granuliberin R is a new mast cell degranulating peptide comes from amphibian, can be isolated from the skin of frog Rana rugosa. Granuliberin R is a dodecapeptide, can act on rat peritoneal mast cell to liberate granules and release histamine .
|
- HY-P4086
-
|
|
RABV
|
Infection
|
|
Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R), a chimeric peptide consisting of 29 amino acids, is synthesized by adding nona-arginine motif to the carboxy terminus of RVG (rabies virus glycoprotein). Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) is positively charged and able to bind negatively charged nucleic acids via charge interaction .
|
- HY-P5327
-
|
|
Bcl-2 Family
|
Others
|
|
r8 Bid BH3 is a biological active peptide. (The Bid BH3 is a pro-apoptotic member of the 'BH3-only' subset of BCL-2 family proteins that constitute a critical control point in apoptosis. r8BIDBH3 is lethal to human leukemia cell lines that expresse Bcl-2. The Bcl-2 antagonists may have the potential to be efficacious in cancer therapy. Poly-D-arginine (d-isomer as denoted by rrrrrrrr) is fused to the Bid BH3 peptide to facilitate cellular uptake of the peptide.)
|
- HY-P4403
-
|
(Z-Asp-Glu-Val-Asp)₂-Rhodamine 110
|
Fluorescent Dye
Apoptosis
Caspase
|
Others
|
|
Z-DEVD-R110 ((Z-Asp-Glu-Val-Asp)2-Rhodamine 110) is a fluorogenic caspase-3/7 substrate. Z-DEVD-R110 can be used to detect apoptosis. Z-DEVD-R110 is a rhodamine derivative with two four–amino acid (DEVD) peptides linked to the fuorophore .
|
- HY-P11293
-
|
|
Melanocortin Receptor
|
Cancer
|
|
DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .
|
- HY-P3542
-
|
|
GCGR
|
Metabolic Disease
|
|
Des His1, Glu8 Exendin-4 is a potent glucagon-like peptide-1 receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal .
|
- HY-P10055
-
|
PSMA-1
|
PSMA
|
Cancer
|
|
PSMA-1 is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells. PSMA-1 is selected and polyarginine sequences R6 or R9 were added at the C terminus to generate the CTPs. FITC labeling of the peptide with an aminohexanoic acid (Ahx) linker at the N terminus produced FITC-PSMA-1，to track PSMA binding on PCa cells .
|
- HY-P5419
-
|
|
Peptides
|
Others
|
|
WAAG-3R is a biological active peptide. (Aggrecanases belong to the ADAMTS (A disintegrin and metalloprotease with thrombospondin motif) family of proteases. Aggrecanases cleave aggrecan, the major structural component of cartilage. Aggrecanase-1 (ADAMTS-4) is a major aggrecanase in human osteoarthritic cartilage. This FRET peptide was used in an ADAMTS-4 (Aggrecanase-1) and ADAMTS-5 (Aggrecanase-2) assay . (Ex/Em = 340/420 nm)
|
- HY-P4146
-
|
BI 456906
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
- HY-P5419A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
WAAG-3R TFA is a biological active peptide. (Aggrecanases belong to the ADAMTS (A disintegrin and metalloprotease with thrombospondin motif) family of proteases. Aggrecanases cleave aggrecan, the major structural component of cartilage. Aggrecanase-1 (ADAMTS-4) is a major aggrecanase in human osteoarthritic cartilage. This FRET peptide was used in an ADAMTS-4 (Aggrecanase-1) and ADAMTS-5 (Aggrecanase-2) assay . (Ex/Em = 340/420 nm)
|
- HY-P4043
-
|
|
HBV
|
Infection
Inflammation/Immunology
|
|
Hepatitis b virus pre-s region (120-145) is a preS2 peptide that inhibits the binding of single-chain Fv fragment (scFv) or IgG to r-HBsAg .
|
- HY-P4146A
-
|
BI 456906 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
- HY-P0165B
-
|
ITM077 acetate; R1583 acetate; BIM51077 acetate
|
GLP Receptor
|
Metabolic Disease
|
|
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an Ki value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .
|
- HY-146127
-
|
|
EGFR
|
Others
|
|
Grb2 SH2 domain inhibitor 1 is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
|
- HY-P1531
-
- HY-P1039
-
|
PHCVPRDLSWLDLEANMCLP
|
Raf
|
Cancer
|
|
R18 is a peptide antagonists of 14-3-3, with a KD of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .
|
- HY-146127A
-
|
|
Src
|
Others
|
|
Grb2 SH2 domain inhibitor 1 TFA is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
|
- HY-P5971A
-
|
|
Melanocortin Receptor
|
Metabolic Disease
|
|
TCMCB07 TFA, a cyclic nonapeptide peptide, is an orally active and brain-penetrant melanocortin receptor 4 (MC4R) antagonist. TCMCB07 TFA plays an important role in cachexia .
|
- HY-P1039A
-
|
PHCVPRDLSWLDLEANMCLP TFA
|
Raf
|
Cancer
|
|
R18 TFA is a peptide antagonists of 14-3-3, with a KD of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .
|
- HY-P1858A
-
|
|
CRFR
|
Cardiovascular Disease
Neurological Disease
Endocrinology
|
|
Urocortin III, mouse TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2 . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .
|
- HY-P1858
-
|
|
CRFR
|
Cardiovascular Disease
Neurological Disease
Endocrinology
|
|
Urocortin III, mouse is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2 . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .
|
- HY-P11086
-
|
|
Bacterial
|
Infection
|
|
c(R3W4V) is an antimicrobial peptide. c(R3W4V) has a relatively stable transmembrane structure. c(R3W4V) has IC50 values of 0.27 μM, 0.46 μM, and 0.05 μM for E. coli, S. aureus, and B. subtilis, respectively .
|
- HY-P4899
-
|
|
Beta-secretase
|
Neurological Disease
|
|
RE (EDANS) EVNLDAEFK (DABCYL) R is an EDANS and DABCYL double-labeled peptide，serves as a fluorescent substrate for BACE1(Em=360nm，Ex=528nm). RE (EDANS) EVNLDAEFK (DABCYL) R can be used for BACE1 activity measurement and the enzyme activity level is directly proportional to the fluorescence reaction .
|
- HY-P2191
-
|
|
Kisspeptin Receptor
|
Endocrinology
|
|
KISS1-305, the Metastin/Kisspeptin analog, is a prototype peptide and a chemical probe. KISS1-305 has suboptimal KISS1R agonistic activity, and resists plasma protease degradation .
|
- HY-P3375
-
|
IBI-362; LY-3305677; OXM-3
|
GCGR
GLP Receptor
|
Metabolic Disease
|
|
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .
|
- HY-W006886
-
|
|
Amino Acid Derivatives
|
Others
|
|
Fmoc-(R)-2-(7-octenyl)Ala-OH is an amino acid derivative with an Fmoc protecting group that can be used to synthesize inhibitor peptides that combinatorially inactivate ErbB1, ErbB2, and ErbB3 .
|
- HY-P10815
-
|
|
Apoptosis
Calcium Channel
|
Others
|
|
IP3RCYT is an IP3R inhibitory peptide, which can inhibit the binding of cytochrome C to IP3R with an IC50 about 100 nM. IP3RCYT regulates calcium signaling within cells. P3RCYT inhibits apoptosis in HeLa and Jurkat cells treated with Staurosporine (HY-15141) or Membrane-bound Fas ligand (FasL) .
|
- HY-P3375A
-
|
IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA
|
GCGR
GLP Receptor
|
Metabolic Disease
|
|
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .
|
- HY-P5971
-
|
Mifomelatide
|
Melanocortin Receptor
|
Metabolic Disease
|
|
TCMCB07, a cyclic nonapeptide peptide, is an orally active and brain-penetrant melanocortin receptor 4 (MC4R) antagonist. TCMCB07 plays an important role in cachexia. TCMCB07 has potential transport capabilities .
|
- HY-P1074
-
SNX-482
1 Publications Verification
|
Calcium Channel
|
Neurological Disease
|
|
SNX-482, a peptide, is a potent, high affinity, selective and voltage-dependent R-type CaV2.3 channel blocker with an IC50 of 30 nM. SNX-482 has antinociceptive effect .
|
- HY-P4099
-
|
|
Peptides
|
Others
|
|
Cys(Npys)-(D-Arg)9 is an amphipathic R9 cell penetrating peptide (CPP). Cys(Npys)-(D-Arg)9 has cytotoxicity for microspore cells with the amount higher than 1 nmol .
|
- HY-P2516
-
|
|
Tau Protein
|
Neurological Disease
|
|
Tau Peptide (275-305) (Repeat 2 domain) is the Alzheimer's Tau fragment R2, corresponding to the second repeat unit of the microtubule-binding domain, which is believed to be pivotal to the biochemical properties of full tau protein. Tau Peptide (275-305) specifically coordinates with group IIB metal ions (Zn²⁺, Cd²⁺, Hg²⁺), which can induce their conformational changes and significantly promote their pathological accumulation. Tau Peptide (275-305) can be used to study the role of heavy metals in neurodegenerative diseases .
|
- HY-P10256A
-
|
|
Kisspeptin Receptor
PKA
PKC
|
Endocrinology
|
|
Kiss2 peptide acetate is the acetate form of Kiss2 pepride (HY-P10256). Kiss2 peptide acetate is a positive regulator of reproduction. Kiss2 peptide acetate binds with its cognate receptor Kiss2R (GPR54) in COS-7 cells, activates PKA and PKC signaling pathways through Gas and Gaq proteins, and thus enhances the activity of cAMP response element-dependent luciferase (CRE-luc) and serum response element-dependent luciferase (SRE-luc) .
|
- HY-P11089
-
|
|
MHC
|
Cancer
|
|
TP53 neoepitope is a high-affinity antigenic peptide targeting HLA-A. TP53 neoepitope can triggers CD8 + T cell-mediated killing of TP53-mutant tumor cells. TP53 neoepitope is promising for research of solid tumors harboring TP53 hotspot mutations (e.g., R175H, R273H) .
|
- HY-P3873
-
- HY-P10256
-
|
|
Kisspeptin Receptor
PKA
PKC
|
Endocrinology
|
|
Kiss2 peptide is a positive regulator of reproduction. Kiss2 peptide binds with its cognate receptor Kiss2R (GPR54) in COS-7 cells, activates PKA and PKC signaling pathways through Gas and Gaq proteins, and thus enhances the activity of cAMP response element-dependent luciferase (CRE-luc) and serum response element-dependent luciferase (SRE-luc) .
|
- HY-P10975
-
|
|
SARS-CoV
Influenza Virus
Enterovirus
|
Infection
|
|
P9R is an antiviral peptide. P9R has broad-spectrum antiviral activities against the coronaviruses (SARS-CoV-2, MERS-CoV and SARS-CoV), A(H1N1)pdm09, A(H7N9) virus, and rhinovirus. P9R directly binds to viruses and inhibits virus-host endosomal acidification. P9R significantly protects mice from A(H1N1)pdm09 infection without generating drug-resistant virus. P9R can be used for pH-dependent respiratory viruses research .
|
- HY-P10018
-
|
SAR425899
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes .
|
- HY-P5369
-
|
|
Peptides
|
Others
|
|
[Arg6]-β-Amyloid (1-42), england mutation is a biological active peptide. (Several mutations in the beta amyloid precursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds.Tthe English (H6R) mutation will disrupt H6 interactions.)
|
- HY-P4139
-
|
|
Peptides
|
Others
|
|
activable cell-penetrating peptide (ACCP) consists of a polycationic CPP (typically arg9 or r9) connected via a cleavable linker to a matching polyanion (typically glu9 or e9), which reduces the net charge to nearly zero and thereby inhibits adhesion and uptake into cells .
|
- HY-P5247A
-
|
PTP20 TFA
|
Melanocortin Receptor
Sirtuin
|
Metabolic Disease
Inflammation/Immunology
|
|
Palmitoyl tetrapeptide-20 (PTP20) TFA is a biomimetic peptide agonist of α-MSH. Palmitoyl tetrapeptide-20 TFA promotes hair pigmentation and delays hair graying by activating the MC1-R pathway (AC50: 0.16 nM), enhancing catalase activity to reduce H2O2 accumulation, and upregulating SIRT1 activity. Palmitoyl tetrapeptide-20 TFA can be used in research on preventing hair loss and improving hair graying .
|
- HY-P5247
-
|
PTP20
|
Melanocortin Receptor
Sirtuin
|
Metabolic Disease
Inflammation/Immunology
|
|
Palmitoyl tetrapeptide-20 (PTP20) is a biomimetic peptide agonist of α-MSH. Palmitoyl tetrapeptide-20 promotes hair pigmentation and delays hair graying by activating the MC1-R pathway (AC50: 0.16 nM), enhancing catalase activity to reduce H2O2 accumulation, and upregulating SIRT1 activity. Palmitoyl tetrapeptide-20 can be used in research on preventing hair loss and improving hair graying .
|
- HY-P5645
-
LEAP-2
1 Publications Verification
Human liver expressed antimicrobial Peptide-2
|
GHSR
Interleukin Related
IFNAR
TNF Receptor
Bacterial
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
LEAP-2 (Human liver expressed antimicrobial peptide-2) is a GHS-R1a antagonist, with an IC50 of 6.0 nM. LEAP-2 suppresses the orexigenic effect of ghrelin. LEAP-2 attenuates ghrelin-induced growth hormone (GH) release and reduces basal food intake. LEAP-2 exhibits antimicrobial activity against microbial model organisms. LEAP-2 can be used for the study of obesity and infection .
|
- HY-P10358A
-
|
|
Calcium Channel
|
Neurological Disease
|
|
TAT-CBD3A6K acetate, is a modified TAT-CBD3 peptide. TAT-CBD3A6K acetate reduces T- and R-type voltage-dependent calcium currents in dorsal root ganglion (DRG) neurons. TAT-CBD3A6K acetate shows anti-nociceptive effects in a model of AIDS-induced peripheral neuropathy by preventing CRMP-2-mediated enhancement of T- and R-type calcium channel function .
|
- HY-P3736
-
|
MP-2
|
Interleukin Related
|
Cancer
|
|
Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research .
|
- HY-P10358
-
|
|
Calcium Channel
|
Neurological Disease
|
|
TAT-CBD3A6K, is a modified TAT-CBD3 peptide. TAT-CBD3A6K reduces T- and R-type voltage-dependent calcium currents in dorsal root ganglion (DRG) neurons. TAT-CBD3A6K shows anti-nociceptive effects in a model of AIDS-induced peripheral neuropathy by preventing CRMP-2-mediated enhancement of T- and R-type calcium channel function .
|
- HY-P10827
-
|
|
Complement System
|
Inflammation/Immunology
|
|
PIC1 PA, a 15 amino-acid peptide, is a potent PIC1 analog that inhibits classical pathway mediated complement activation. PIC1 PA functionally disrupts the C1s-C1r-C1r-C1s/MASPs interaction with collagen-like region (CLR) of C1q/MBL, respectively. PIC1 PA specifically binds to the CLR of C1q and bounds to purified C1q with a mean equilibrium dissociation constant (KD) of 33.3 nM .
|
- HY-103277A
-
|
|
Bombesin Receptor
|
Neurological Disease
Metabolic Disease
|
|
BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca 2+ release .
|
- HY-103277
-
|
|
Bombesin Receptor
|
Neurological Disease
Metabolic Disease
|
|
BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca 2+ release .
|
- HY-P10489
-
|
|
Kisspeptin Receptor
|
Cancer
|
|
Kisspeptin-14 human is a peptide hormone encoded by the KiSS-1 gene. Kisspeptin-14 human, along with several other similar peptide hormones, is produced from a common precursor protein by cleavage by different proteases. Kisspeptin-14 human is an endogenous ligand of KISS1R. Kisspeptin-14 human has the same receptor binding efficiency and potency as full-length kisspeptin. Kisspeptin-14 human binds to its receptor GPR54 and is able to activate this G protein-coupled receptor and activate multiple intracellular signaling pathways. Kisspeptin-14 human can be used to study reproductive development and tumor metastasis .
|
- HY-P11312
-
|
|
Neurokinin Receptor
|
Neurological Disease
|
|
[S5K, F6Y, L9mL, M10Mox] neurokinin A (4–10) is a neuropeptide A analog and a peptide fragment of HY-P10746. [S5K, F6Y, L9mL, M10Mox] neurokinin A (4–10) is highly selective for mouse tachykinin receptors and human tachykinin receptor NK1R and has an in vivo half-life of 10.3 hours in mice .
|
- HY-P0097A
-
|
Melanostatine-5 acetate salt
|
Melanocortin Receptor
|
Metabolic Disease
Endocrinology
Cancer
|
|
Nonapeptide-1 (Melanostatine-5) acetate salt, a peptide hormone, is a selective antagonist of MC1R (Ki: 40 nM). Nonapeptide-1 acetate salt is a competitive α-MSH antagonist that potently inhibits intracellular cAMP and melanosome dispersion induced by α-MSH in melanocytes (IC50: 2.5 nM and 11 nM, respectively). Nonapeptide-1 acetate salt inhibits melanin synthesis, and can be used in the research of skin pigmentation and regulation of steroid production in the adrenal gland, skin cancer .
|
- HY-113893
-
|
|
Peptides
|
Inflammation/Immunology
|
|
β-Interleukin I (163-171), human, an immunostimulatory fragment of human IL-1β peptide, is a T cell activator. β-Interleukin I (163-171), human is not an IL-1R-binding domain of IL-1β. β-Interleukin I (163-171), human is a potent adjuvant that enhances the immune response in a variety of exptl. situations .
|
- HY-P0097
-
|
Melanostatine-5
|
Melanocortin Receptor
|
Metabolic Disease
Endocrinology
Cancer
|
|
Nonapeptide-1 (Melanostatine-5), a peptide hormone, is a selective antagonist of MC1R (Ki: 40 nM). Nonapeptide-1 is a competitive α-MSH antagonist that potently inhibits intracellular cAMP and melanosome dispersion induced by α-MSH in melanocytes (IC50: 2.5 nM and 11 nM, respectively). Nonapeptide-1 inhibits melanin synthesis, and can be used in the research of skin pigmentation and regulation of steroid production in the adrenal gland, skin cancer .
|
- HY-P1110
-
AF12198
4 Publications Verification
|
Interleukin Related
|
Inflammation/Immunology
|
|
AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 µM) or the murine type I receptor (IC50>200 µM). AF12198 inhibits IL-1-induced IL-8 production (IC50=25 nM) and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression (IC50=9 nM) in vitro. AF12198 has anti-inflammatory activities and blocks responses to IL-1 in vivo .
|
- HY-13948
-
|
Angiotensin II; Ang II; DRVYIHPF
|
Angiotensin Receptor
Apoptosis
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Angiotensin II (Angiotensin II) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human also induces apoptosis. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
|
- HY-13948A
-
|
Angiotensin II acetate; Ang II acetate; DRVYIHPF acetate
|
Angiotensin Receptor
Apoptosis
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Angiotensin II human (Angiotensin II) acetate is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human acetate plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human acetate stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human acetate induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human acetate also induces apoptosis. Angiotensin II human acetate induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
|
- HY-P3019
-
|
|
CRFR
|
Cardiovascular Disease
Neurological Disease
Endocrinology
|
|
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) selectively binds to type 2 CRF receptors with Ki values of 13.5, 21.7, and >100 nM for mCRF2β, rCRF2α, and hCRF1, respectively. Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .
|
- HY-13948B
-
|
Angiotensin II TFA; Ang II TFA; DRVYIHPF TFA
|
Angiotensin Receptor
Apoptosis
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Angiotensin II human (Angiotensin II) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human TFA induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human TFA also induces apoptosis. Angiotensin II human TFA induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
|
- HY-P1925A
-
|
|
PI3K
Reactive Oxygen Species (ROS)
Apoptosis
|
Cancer
|
|
GO-203 TFA is a potent MUC1-C oncoprotein inhibitor. GO-203 TFA is an all D-amino acid peptide that consists of a poly-R transduction domain linked to a CQCRRKN motif that binds to the MUC1-C cytoplasmic tail and blocks MUC1-C homodimerization. GO-203 TFA downregulates TIGAR (TP53-induced glycolysis and apoptosis regulator) protein synthesis by inhibiting the PI3K-AKT-S6K1 pathway. GO-203 TFA induces the production of ROS and loss of mitochondrial transmembrane potential. GO-203 TFA inhibits the growth of colon cancer cells in vitro and as xenografts in nude mice .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P990013
-
|
Glutazumab; GMA-102; GMA-105
|
GCGR
|
Metabolic Disease
|
|
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R .
|
-
- HY-P991511
-
|
|
PACAP Receptor
|
Neurological Disease
|
|
ALD1910 is a humanized monoclonal antibody against PACAP38 and PACAP27. ALD1910 blocks PACAP signaling through the pituitary adenylate cyclase-activating peptide type I receptor (PAC1-R), vasoactive intestinal peptide receptor 1 (VPAC1-R), and VPAC2-R. ALD1910 recognizes a nonlinear epitope within PACAP and blocks its binding to the cell surface. ALD1910 can be used for the study of PACAP-mediated migraine .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-13948
-
|
Angiotensin II; Ang II; DRVYIHPF
|
Natural Products
Classification of Application Fields
Source classification
Endogenous metabolite
Disease Research Fields
Endocrinology
Cancer
|
Angiotensin Receptor
Apoptosis
|
|
Angiotensin II (Angiotensin II) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human also induces apoptosis. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-13948BS
-
|
|
|
Angiotensin II human- 13C6, 15N TFA (Ang II- 13C6, 15N TFA) is 13C- and 15N-labeled Angiotensin II human (TFA) (HY-13948B). Angiotensin II human (Angiotensin II) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions .
|
-
| Cat. No. |
Compare |
Product Name |
Application |
Reactivity |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Host |
|
| Reactivity |
|
| Application |
|
Dilution
Ratio |
|
| Molecular Weight |
|
| Conjugation |
|
| Clonality |
|
| Immunogen |
|
| Appearance |
|
| Isotype |
|
| Gene ID |
|
| SwissProt ID |
|
| Purity |
|
| Formulation |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-106203B
-
|
(R)-SSR-125543
|
|
Alkynes
|
|
(R)-Crinecerfont is the R-enantiomer of Crinecerfont (HY-106203). Crinecerfont (SSR-125543) is a potent, orally active, non-peptide CRF1 receptor antagonist. Crinecerfont can be used for Classic congenital adrenal hyperplasia (CAH) research. Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-172276A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG2000-R8 can be used for drug delivery .
|
-
- HY-172276
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG1000-R8 can be used for drug delivery .
|
-
- HY-172276B
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG5000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG5000-R8 can be used for drug delivery .
|
-
- HY-172277B
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG5000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG5000-R9 can be used for drug delivery .
|
-
- HY-172277A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG2000-R9 can be used for drug delivery .
|
-
- HY-172277
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG1000-R9 can be used for drug delivery .
|
-
- HY-172272B
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG5000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-172272A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-172272
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-172711
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-R6H4 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (R6H4). R6H4 can be used for pH responsive anticancer drug delivery purposes. DSPE-PEG2000-R6H4 can be used for drug delivery .
|
-
- HY-172712
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG3000-R6H4 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (R6H4). R6H4 can be used for pH responsive anticancer drug delivery purposes. DSPE-PEG3000-R6H4 can be used for drug delivery .
|
-
- HY-172710
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-R6H4 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (R6H4). R6H4 can be used for pH responsive anticancer drug delivery purposes. DSPE-PEG1000-R6H4 can be used for drug delivery .
|
-
- HY-172495
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG3000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3000-iRGD can be used for drug delivery .
|
-
- HY-172493
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery .
|
-
- HY-172494
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for drug delivery .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![[S5K, F6Y, L9mL, M10Mox] neurokinin A (4–10)](http://file.medchemexpress.eu/product_pic/hy-p11312.gif)
